Wockhardt Share Price Target 2024 to 2030 Wockhardt Limited, a prominent pharmaceutical and biotechnology company based in Mumbai, India, has gained significant attention from investors due to its impressive performance in recent years. The company operates a vast portfolio of drugs, including generic medicines, biopharmaceuticals, and vaccines, and has a solid presence in the U.S., U.K., and India. Its ongoing investment in research and development (R&D) and expansion into high-demand areas such as biosimilars and vaccines has fueled its growth. This article will provide a detailed analysis of Wockhardt’s share price projections from 2024 to 2030, focusing on its financial performance, market potential, and growth drivers
Wockhardt Share Price Target
Wockhardt Share Price Target From 2024 ₹1,456, 2025 ₹2,554, 2026 ₹3,678, 2027 ₹4,875, 2028 ₹5,996, 2029 ₹7,225 To 2030 ₹8,345
Wockhardt Share Price Target From 2024 To 2030
Year | Projected Wockhardt Share Price |
2024 | ₹1,456 |
2025 | ₹2,554 |
2026 | ₹3,678 |
2027 | |
2028 | ₹5,996 |
2029 | ₹7,225 |
2030 | ₹8,345 |
Category | |
See More:
Bhel Share Price Target
A2Z Infra Engineering Share Price Target
Yes Bank Share Price Target
Wockhardt Shareholding Pattern
Category | Shareholding Percentage |
Promoters | 51.99% |
Retail Investors and Others | 36.23% |
Foreign Institutional Investors | 6.70% |
Mutual Funds | |
Other Domestic Institutions | 2.14% |
Wockhardt Financial Data
Metric | Value |
Open Price | ₹1,315 |
52-week High | |
52-week Low | ₹232.40 |
Current Market Price | ₹1,268 |
Market Capitalization | ₹19,430 Crore |
Dividend Yield | NA |
P/E Ratio | NA |
Wockhardt Share Price Target 2024, 2025, 2026, 2027, 2028, 2029 To 2030
Wockhardt Share Price Target From 2024 ₹1,456, 2025 ₹2,554, 2026 ₹3,678, 2027 ₹4,875, 2028 ₹5,996, 2029 ₹7,225 To 2030 ₹8,345 Wockhardt’s market capitalization as of the latest data stands at ₹19,430 Crore, with its stock price showing impressive growth. The absence of a dividend yield and P/E ratio may suggest that the company is reinvesting its earnings into further expansion.
See More: IRFC Share Price Target
Wockhardt Net Worth
Metric | Value |
Total Net Worth | ₹19,430 Crore |
Yearly Revenue | |
R&D Investment (2023) | ₹700 Crore |
The net worth of Wockhardt is substantial, with a healthy yearly revenue stream. The company is also heavily investing in R&D, underscoring its commitment to innovation and future growth.
Wockhardt Salary and Executive Compensation
Executive | Salary (Annual) |
CEO/MD | ₹3 Crore |
CFO | ₹1.5 Crore |
R&D Head | |
The salaries of Wockhardt’s executives are aligned with the company’s performance and growth potential. These figures reflect the leadership’s compensation and their focus on driving Wockhardt’s growth.
See More: Adani Green Energy Share Price Target
Wockhardt Share Price Drivers
Factor | Impact on Share Price |
R&D and Innovation | High growth potential |
Global Market Expansion | Increased revenues |
Institutional Investment | Boosts investor confidence |
De-leveraging (Unpledged Shares) | Increased investor trust |
Regulatory Approvals | |
The primary growth drivers for Wockhardt include its focus on R&D, the expansion into global markets, institutional backing, and the management’s focus on reducing debt by unpledging promoter shares.
Wockhardt Risks and Challenges
Risk Factor | Impact on Share Price |
Regulatory Delays | Potential stock p rice dip |
Drug Approval Failures | High volatility |
Economic Downturns | Reduced demand in emerging markets |
Competitive Pressure | Lower market share growth |
Although Wockhardt is a promising stock, there are inherent risks such as regulatory challenges and economic downturns that could lead to fluctuations in its stock price.
See More: RVNL Share Price Target
Wockhardt Future Outlook (2024 to 2030)
Year | Outlook |
2024 | Stable growth with a price target of ₹1,456 |
2025 | Continued growth from product launches, price target of ₹2,554 |
2026 | Increased market share, especially in biopharmaceuticals, price target of ₹3,678 |
2027 | Further expansion in Europe and the U.S., price target of ₹4 ,875 |
2028 | Strong vaccine and antibiotic growth, price target of ₹5,996 |
2029 | Significant growth in biosimilars, price target of ₹7,225 |
2030 | Long-term growth driven by innovative products, price target of ₹8,345 |
